Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study

Published:2018-04-17 Issue:8 Volume:20 Page:1983-1987
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Kosiborod Mikhail¹,Birkeland Kåre I.²,Cavender Matthew A.³,Fu Alex Z.⁴,Wilding John P.⁵,Khunti Kamlesh⁶,Holl Reinhard W.⁷,Norhammar Anna⁸⁹,Jørgensen Marit E.¹⁰¹¹,Wittbrodt Eric T.¹²,Thuresson Marcus¹³,Bodegård Johan¹⁴,Hammar Niklas⁸¹⁵,Fenici Peter¹⁶,

Affiliation:

1. Department of Cardiovascular Diseases, Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City; Kansas City Missouri

2. University of Oslo and Oslo University Hospital; Oslo Norway

3. Department of Medicine, University of North Carolina; Chapel Hill North Carolina

4. Georgetown University Medical Center; Washington District of Columbia

5. Obesity and Endocrinology Research Group, University of Liverpool; Liverpool UK

6. Leicester Diabetes Centre, University of Leicester; Leicester UK

7. Institute of Epidemiology and Medical Biometry, University of Ulm; Ulm Germany

8. Karolinska Institutet; Stockholm Sweden

9. Capio S:t Görans Hospital; Stockholm Sweden

10. Steno Diabetes Center; Copenhagen Denmark

11. National Institute of Public Health, Southern Denmark University, Odense; Denmark

12. Health Economics and Outcomes Research, AstraZeneca; Wilmington Delaware

13. Statisticon AB; Uppsala Sweden

14. AstraZeneca Nordic-Baltic; Oslo Norway

15. AstraZeneca R&D; Gothenburg Sweden

16. Global Medicines Development, AstraZeneca; Cambridge UK

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13299/fullpdf

Reference12 articles.

1. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

2. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

3. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study;Kosiborod;Circulation,2017

4. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study;Persson;Diabetes Obes Metab,2018

5. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis;Birkeland;Lancet Diabetes Endocrinol,2007

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and cerebrovascular diseases: a meta-analysis of controlled clinical trials;Frontiers in Endocrinology;2024-08-23

2. Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials;European Heart Journal - Cardiovascular Pharmacotherapy;2024-07-17

3. SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis;Frontiers in Cardiovascular Medicine;2024-01-11

4. Cardiovascular protective effect of sodium-glucose cotransporter 2 inhibitors on patients with acute coronary syndrome and type 2 diabetes mellitus: a retrospective study;BMC Cardiovascular Disorders;2023-10-07

5. Sodium‐Glucose Cotransporter‐2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population‐Based Investigation;Journal of the American Heart Association;2023-07-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3